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introduction: Preoperative mapping of motor areas with navigated transcranial mag-
netic stimulation (nTMS) has been shown to improve surgical outcomes for peri-Rolandic 
lesions and, in particular, for gliomas. However, the impact of this technique on surgical 
outcomes for peri-Rolandic metastatic lesions is yet unknown.
Objective: To investigate the impact of nTMS on surgical outcomes for peri-Rolandic 
metastatic lesions, various clinical parameters were analyzed in our international study 
group.
Methods: Two prospectively enrolled cohorts were compared by investigating patients 
receiving preoperative nTMS (2010–2015; 120 patients) and patients who did not 
receive preoperative nTMS (2006–2015; 130 patients). Tumor location, pathology, size, 
and preoperative deficits were comparable.
results: The nTMS group showed a lower rate of residual tumor on postoperative mag-
netic resonance imaging (odds ratio 0.3025; 95% confidence interval 0.1356–0.6749). 
On long-term follow-up, surgery-related paresis was decreased in the nTMS group 
(nTMS vs. non-nTMS; improved: 30.8 vs. 13.1%, unchanged: 65.8 vs. 73.8%, worse: 
3.4 vs. 13.1% of patients; p =  0.0002). Moreover, the nTMS group received smaller 
craniotomies (nTMS: 16.7 ±  8.6 cm2 vs. non-nTMS: 25.0 ±  17.1 cm2; p <  0.0001). 
Surgical time differed significantly between the two groups (nTMS: 128.8 ± 49.4 min vs. 
non-nTMS: 158.0 ± 65.8 min; p = 0.0002).
Abbreviations: AP, anterior–posterior; BMRC, British Medical Research Council; CI, confidence interval; CNS, central nervous 
system; CST, corticospinal tract; CT, computed tomography; DCS, direct cortical stimulation; DTI, diffusion tensor imaging; 
DTI FT, diffusion tensor imaging fiber tracking; EMG, electromyography; EOR, extent of resection; GTR, gross total resec-
tion; fMRI, functional magnetic resonance imaging; IOM, intraoperative neuromonitoring; MEG, magnetoencephalography; 
MEP, motor-evoked potential; MRI, magnetic resonance imaging; nTMS, navigated transcranial magnetic stimulation; OR, 
odds ratio; rMT, resting motor threshold; SRS, stereotactic radiosurgery; STR, subtotal resection; TMS, transcranial magnetic 
stimulation.
TaBle 1 | Patient data.
nTMs non-nTMs p-Value
Mean age (years ± SD) 59.1 ± 11.9 62.3 ± 12.4 0.0394
Gender (%) Male 48.3 51.5 0.6126
Female 51.7 48.5
Preoperative 
 paresis (%)
None 48.3 60.8 0.1283
Mild 33.3 26.9
Severe 18.4 12.3
Location (%) Frontal lobe 72.5 69.2 0.5701
Parietal lobe 27.5 30.8
Histology (%) NSCLC 35.7 31.5 0.2146
Breast 16.3 18.5
Melanoma 10.2 18.5
Colon 7.1 8.1
RCC 5.1 7.3
Seminoma 3.1 0.0
Other 22.5 16.1
Mean tumor diameter (cm) 2.8 ± 1.1 3.1 ± 1.4 0.0610
Mean follow-up (months) 9.9 ± 10.5 9.8 ± 10.8 0.9588
Detailed overview on age, gender, preoperative neurological status, location, histology, 
tumor diameter, and mean follow-up.
NSCLC, non-small cell lung cancer; RCC, renal cell cancer. Preoperative paresis: none, 
no paresis; mild, British Medical Research Council (BMRC) grade of muscle strength 
≥4/5; severe, BMRC grade of muscle strength ≤3/5.
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conclusion: This non-randomized study suggests that preoperative motor mapping by 
nTMS may improve the treatment of patients undergoing surgical resection of metas-
tases in peri-Rolandic regions. These findings suggest that further evaluation with a 
prospective, randomized trial may be warranted.
Keywords: brain metastases, matched pair, preoperative mapping, rolandic region, transcranial magnetic 
stimulation
inTrODUcTiOn
One indication for surgical resection of cerebral metastases is a 
focal motor deficit. In these patients, early surgery is often recom-
mended so as to preserve existing function and, hopefully, to allow 
recovery of lost function. In these cases, surgeons must frequently 
contend with a lesion or lesions that threaten the motor cortex or 
subcortical motor tracts, and any technique that helps to identify 
and preserve those functional regions is valuable (1).
Continuous motor-evoked potential (MEP) monitoring 
and subcortical electrical stimulation are two well-established 
techniques to monitor and map functional integrity of the motor 
system. Another technique, navigated transcranial magnetic 
stimulation (nTMS), which uses magnetic pulses to activate small 
regions of cortex, has demonstrated the ability to map the motor 
system in the preoperative setting. For supratentorial lesions 
located in motor eloquent areas, especially gliomas, three prior 
studies have demonstrated improvement in outcomes when pre-
operative functional mapping of motor areas is also performed 
by nTMS (2–4).
In comparison to other preoperative mapping techniques 
such as functional magnetic resonance imaging (fMRI) and 
magnetoencephalography (MEG), nTMS correlates better with 
intraoperative direct cortical stimulation (DCS) (5, 6). This cor-
relation has been validated in international studies, which have 
also shown nTMS to be a helpful tool for surgical planning (6, 7).
Although the positive impact of nTMS on surgical indication, 
approach planning, and functional outcome has been shown for 
gliomas, similar effects have yet to be demonstrated in the man-
agement of metastatic lesions (2–4). This multicenter study aims 
to compare the surgical outcome of patients with motor eloquent 
metastatic lesions who received preoperative nTMS-based motor 
mapping with those that did not. In so doing, we aim to character-
ize the impact of preoperative nTMS in the management of these 
challenging lesions.
MaTerials anD MeThODs
investigated Patient cohorts
Inclusion criteria were (1) planned resection of one supratentorial 
metastasis and (2) anatomical association between tumor and 
Rolandic cortex as seen on magnetic resonance imaging (MRI). 
Eligibility for surgery was discussed on a case-by-case basis with 
each patient and reviewed by an interdisciplinary tumor board, 
which included a practitioner of stereotactic radiosurgery (SRS). 
A plan for surgical resection required the consent of all disciplines 
(neurosurgery, neurooncology, radiation oncology, and medical 
oncology) according to the present guidelines (8, 9). Surgery 
was recommended for patients presenting with disabling motor 
weakness or progressive disease despite chemo- or radiotherapy. 
In all centers, the surgical goal was complete resection. Primary 
SRS was the treatment of choice for patients with small tumors 
(relative cutoff value 2 cm max. diameter) who did not meet the 
aforementioned criteria.
Between 2010 and 2015, 120 consecutive patients with pre-
sumed motor eloquent supratentorial metastatic lesions were 
prospectively enrolled and underwent craniotomy in the three 
participating institutions. Presumed motor eloquent location was 
defined as a location of the lesion in or adjacent to the precentral 
gyrus on contrast-enhanced T1 MRI images. A control group 
of 130 consecutive patients who did not undergo nTMS due to 
organizational reasons (missing staff, maintenance, or technical 
problems) were identified and analyzed as well. This control 
group contained patients from each institution and included 
cases performed from 2006 to 2015 with a comparable distribu-
tion of tumor types, tumor locations, and treatment modalities. 
The characteristics of the nTMS and the non-nTMS group are 
outlined in Table 1. With the exception of tumor size, both groups 
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were highly comparable. Only mean tumor diameter differed by 
3.0 mm (Table 1). Data analysis was performed blinded to the 
assigned group. Mean follow-up for clinical evaluation in the out-
patient departments was 9.9 ± 10.5 months (median 6.0 months, 
range 0.3–57.0  months) in the nTMS and 9.8 ±  10.8  months 
(median 5.0 months, range 0.3–55.1 months) in the non-nTMS 
group.
ethics approval and consent to 
Participate
This study was approved by the local institutional review 
boards of all three centers according to ethical standards of the 
Declaration of Helsinki. Written informed consent was obtained 
prior to every nTMS examination from each patient. Ethics 
Committee Registration Numbers: 2793/10, 5497/12, 10-02932, 
and EA4/007/06.
Perioperative Mri
All enrolled patients underwent preoperative MRI scans using 
3-T MR scanners in combination with 8-channel phased 
array head coils (Achieva 3  T, Philips Medical Systems, The 
Netherlands B.V.; Siemens Magnetom 3  T, Munich, Germany; 
GE Excite 3  T, Fairfield, CT, USA) for contrast-enhanced 3D 
gradient echo sequence, FLAIR, and diffusion tensor imaging 
(DTI). The contrast-enhanced 3D gradient echo sequence dataset 
was transferred to the nTMS system (eXimia 3.2 and eXimia 4.3, 
Nexstim Oy, Helsinki, Finland). Depending on each institution’s 
standards, every patient underwent either a contrast-enhanced 
postoperative computed tomography (CT) or MRI scan the day 
after surgery to evaluate the extent of resection (EOR). MRI 
included T1 sequences (±contrast enhancement), diffusion-
weighted imaging to detect any postoperative ischemic events, 
and FLAIR. Unexpected residual tumor was defined as the pres-
ence of residual tumor on postoperative MRI scans despite the 
surgeon’s impression being stated as gross total resection (GTR). 
For regular follow-up examinations, MRI scans were performed 
every 3 months and reviewed for recurrent metastases since neu-
rological status during follow-up was only considered without 
tumor recurrence. Moreover, all performed MRI and CT scans 
were evaluated in regular imaging meetings including board 
certified neurosurgeons and neuroradiologists.
Since craniotomy was also compared between groups, crani-
otomy size was analyzed by postoperative MRI or CT scans in 
all 250 patients. Analysis was done on a case-by-case basis by 
a neurosurgeon; by doing so, we took account for oval-shaped 
as well as rectangular bone flaps. Anterior–posterior (AP) and 
lateral extent of craniotomy were evaluated as well.
clinical assessment
Clinical assessment was performed by experienced neurosurgi-
cal staff including nurse practitioners, residents, and attending 
surgeons. All patients were evaluated for muscle strength, sensory 
function, and coordination before surgery. After surgery, neuro-
logical status was assessed again after awakening from anesthesia 
and each day until discharge, again at 6–8 weeks postoperatively, 
and during clinical follow-up visits every 3 months, depending on 
tumor type. New surgery-related motor deficits were differenti-
ated as transient and permanent.
A new or worsened postoperative motor deficit which did not 
return to the preoperative baseline within 8 weeks from surgery 
was defined as a new permanent paresis. A new or worsened post-
operative motor deficit that resolved within the 8-week follow-up 
interval was defined as a transient paresis. Every patient with a new 
motor deficit directly after surgery underwent a postoperative CT 
scan to exclude secondary hemorrhage. Muscle reflex evaluation 
and resection location were used to differentiate postoperative 
supplementary motor area deficits from primary motor area or 
corticospinal tract (CST) deficits.
Motor Mapping by nTMs
The three participating institutions were equally experienced in 
nTMS motor mapping during the enrollment period and used the 
same technique throughout. In brief, the procedure is performed 
as follows: a magnetic coil placed on the patient’s scalp induces 
a transient magnetic field, which then induces a perpendicular 
electric field in the underlying cortex (10–13). The shape, strength, 
and penetration depth of the elicited electric field depend on the 
stimulation intensity, design of the coil, and the shape of the brain 
itself (12, 13). The electric field is able to modulate cortical neu-
ronal activation for the period of stimulation (10, 14), resulting in 
action potentials from the neurons within the affected region (11). 
The action potential is transmitted via the CST to downstream 
muscle groups, the activations of which are measured as MEPs 
by electromyography (EMG) electrodes placed over the muscle 
belly. By integrating a stereotactic neuronavigation system with 
transcranial magnetic stimulation (TMS) (so-called “navigated 
TMS,” or nTMS), we have gained the ability to individualize the 
mapping procedure to a given patient’s anatomy and identify 
exactly the site of cortical stimulation (15). Thus, nTMS and DCS 
apply the same neurophysiological principles, but nTMS has the 
advantage of being non-invasive.
All enrolled patients of the nTMS group underwent primary 
motor cortex mapping the week before surgery using a widely 
accepted, previously published protocol (6, 16). Briefly, resting 
motor threshold (rMT) was identified first; subsequently, nTMS 
motor mapping was performed using a stimulation intensity of 
110% rMT for the upper and 130% for the lower extremity (6). 
The nTMS mapping session started at the anatomically most 
lateral border of the hand knob and was then performed in 
3–5  mm steps perpendicular to the nearest sulcus until nTMS 
did not evoke any further MEP in any direction. Each cortical 
point at which an MEP above 50 µV was elicited was defined as a 
motor-positive mapping point, and the associated muscle groups 
were identified by examining EMG responses. After an additional 
post  hoc analysis of each stimulation spot, all motor-positive 
mapping points were then exported from the nTMS system to 
the intraoperative neuronavigation system using DICOM format 
files. All three centers used the same two nTMS systems (eXimia 
3.2 and eXimia 4.3, Nexstim Oy, Helsinki, Finland), which use 
a biphasic figure-8 TMS coil with a 50-mm magnetic stimulator 
attached to an infrared tracking system (Polaris Spectra, Waterloo, 
ON, Canada), as previously described (6, 7, 16). All investigators 
underwent manufacturer certification before entering the study.
FigUre 1 | navigated transcranial magnetic stimulation (nTMs) data clarifies functional anatomy for patient counseling. This screenshot demonstrates 
how nTMS data can clarify functional anatomy in this young patient with a large Ewing sarcoma metastasis. Tumor location is shown on contrast-enhanced 
magnetic resonance imaging (MRI) without (a) and with nTMS-positive motor areas (green) including nTMS-based diffusion tensor imaging fiber tracking of the 
corticospinal tract (yellow) (B). The 3D reconstruction (c,D) shows the same coloring including visualization of the tumor in orange, which allows optimal patient 
counseling explaining functional anatomy in relation to the tumor. Postoperative MRI scan shows gross total resection (e).
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intraoperative neuronavigation
Intraoperative neuronavigation (Vector Vision 2®, Vector 
Vision Sky®, or Curve; BrainLAB AG, Feldkirchen, Germany) 
was used in every case in both the nTMS and the non-nTMS 
group. nTMS data were included in the neuronavigation system 
for the nTMS group by exporting nTMS-positive motor areas as 
DICOM files and importing them to the neuronavigation plan-
ning unit (BrainLAB iPlan® Net Cranial 3.0.1; BrainLAB AG, 
Feldkirchen, Germany). nTMS-positive motor areas were fused 
to a 3D image set of a T1-weighted 3D gradient echo sequence 
and FLAIR and defined as objects by simple auto segmentation 
thus making them available as 3D objects for the intraopera-
tive use, as described earlier (17). The process of implementing 
nTMS data into the neuronavigation planning took 2–5 min per 
patient. The result, including nTMS-based DTI fiber tracking 
(DTI FT) for visualization of the CST, is shown in Figure 1.
surgical Technique
Intraoperative neuromonitoring (IOM) was used at the surgeon’s 
discretion, depending on the proximity of the lesion to motor 
eloquent cortex or CST. Identification of CST was based on 
anatomic landmarks in the non-nTMS group. IOM included 
mapping and monitoring by monopolar DCS for evoking MEPs 
as also outlined in earlier reports (18, 19). Surgical technique and 
surgeons’ experience did not vary significantly between groups.
statistical analysis
To test the distribution of several attributes Chi-square or Fisher 
Exact tests were used. Differences between nTMS and non-nTMS 
patients were analyzed by using the Mann–Whitney–Wilcoxon 
test for non-parametric rank comparisons, and the t-test for para-
metric distributions. Level of significance was 0.05 (two-sided) 
for each statistical test, and results are presented as mean ± SD 
as well as odds ratios (ORs) with 95% confidence intervals (CIs) 
(GraphPad Prism 6.0, La Jolla, CA, USA).
resUlTs
nTMs Motor Mapping Prior to surgery
All 120 patients of the nTMS group underwent preoperative map-
ping of the primary motor cortex by nTMS. No patient was unable 
to undergo nTMS, and no adverse events were reported.
influence on surgery
Craniotomy Size
Extension of the craniotomy in the AP direction was 5.0 ± 1.6 cm 
for the nTMS (median 4.5 cm, range 1.8–10.1 cm) and 6.1 ± 2.1 cm 
(median 5.8  cm, range 1.7–13.4  cm) for the non-nTMS group 
(p  <  0.0001; Figure  2A). Lateral craniotomy extension was 
3.4 ± 1.3 cm (median 4.0 cm, range 1.2–6.5 cm) for the nTMS 
and 4.0 ± 1.9 cm (median 3.9 cm, range 1.3–11.0 cm) for the non-
nTMS group (p = 0.0166; Figure 2B). Overall size of the bone flap 
was 16.7 ± 8.6 cm2 (median 16.0 cm2, range 5.1–52.5 cm2) for the 
nTMS and 25.0 ± 17.1 cm2 (median 20.0 cm2, range 6.7–92.0 cm2) 
for the non-nTMS group (p < 0.0001; Figure 2C).
Duration of Surgery
Duration of surgery from incision to end of suture was 
128.8 ±  49.4  min (median 128.0  min, range 30.0–255.0  min) 
for nTMS and 158.0  ±  65.8  min (median 143.0  min, range 
53.0–518.0 min) for non-nTMS patients (p = 0.0002).
Overall clinical Outcome  
in Motor Function
In the nTMS group, there were three patients (2.5%) who suf-
fered from a new surgery-related transient paresis and five 
patients (3.8%) in the non-nTMS group. Concerning new per-
manent pareses, there were 4 patients (3.3%) in the nTMS and 
17 patients (13.1%) in the non-nTMS group (p =  0.0160). We 
also performed a sub-analysis of improvement of preoperative 
pareses. In the nTMS group, 37 patients (30.8%) improved and 
79 (65.8%) remained unchanged; in the non-nTMS group, 17 
FigUre 2 | size of craniotomy. This boxplot of the extent of craniotomy for navigated transcranial magnetic stimulation (nTMS) and non-nTMS patients shows 
with median, min- and max-whiskers, and quartile-boxes the differences between both groups for anterior–posterior (p < 0.0001) (a); and lateral direction 
(p = 0.0166) (B); as well as overall craniotomy size (p < 0.0001) (c).
TaBle 2 | Postoperative course.
nTMs non-nTMs p-Value
Residual tumor (%) 7.7 21.6 0.0024
Unexpected residual (%) 3.4 18.4 0.0002
Surgery-related 
paresis (%)
Improved 30.8 13.1 0.0002
Unchanged 65.8 73.8
Worse 3.4 13.1
None 94.2 83.1 0.0160
Transient 2.5 3.8
Permanent 3.3 13.1
Surgery-related 
complications 
on magnetic 
resonance 
imaging (%)
None 94.2 68.0 <0.0001
Hemorrhage 0.0 13.7
Infection 3.3 5.2
Revision surgery 2.5 13.1
GTR New permanent 
paresis (%)
3.7 11.2 0.0380
No new permanent 
paresis (%)
96.3 88.8
STR New permanent 
paresis (%)
0.0 22.2 0.1213
No new permanent 
paresis (%)
100.0 77.8
The postoperative course of both groups, navigated transcranial magnetic stimulation 
(nTMS) compared to the non-nTMS group, is given. Residual tumor, unexpected 
residual, surgery-related paresis, and  
surgery-related complications as shown by postoperative imaging are displayed. 
Reasons for revision surgery were hemorrhage and corticospinal fluid leakage. In 
addition, the percentage of patients suffering from new permanent motor deficit after 
subtotal (STR) or gross total resection (GTR) according to postoperative imaging for 
both the nTMS and non-nTMS group is displayed.
FigUre 3 | Overall outcome for motor function. This bar chart 
demonstrates the percentage of patients in which paresis in the navigated 
transcranial magnetic stimulation (nTMS) and non-nTMS group improved, 
remained unchanged, or worsened compared to the preoperative state 
(p = 0.0002).
5
Krieg et al. nTMS for Surgery of Brain Metastases
Frontiers in Oncology | www.frontiersin.org December 2016 | Volume 6 | Article 261
patients (13.1%) improved, while 96 patients (73.8%) remained 
unchanged. Moreover, on long-term follow-up of all patients, 4 
patients (3.4%) in the nTMS group and 17 patients (13.1%) in the 
non-nTMS group demonstrated a worsened paresis (p = 0.0002; 
Table 2; Figure 3).
Preoperative Paresis vs. Permanent 
surgery-related Deficit
Preoperative pareses were comparable in both groups (Table 1). 
However, we examined whether clinical outcome might differ in 
both groups depending on preoperative pareses. Concerning the 
effect on functional outcome by the rate of new surgery-related 
pareses, we found 62 patients (51.7%) with preoperative paresis 
in the nTMS and 51 patients (39.2%) in the non-nTMS group 
(Table  1). On long-term follow-up, one patient (1.6%) in the 
nTMS group with preoperative paresis deteriorated permanently, 
compared to three patients (5.2%) without preoperative paresis. 
One patient (1.6%) with paresis and 2 patients (3.4%) without 
paresis showed a transient surgery-related paresis, while 60 
patients (96.8%) with and 53 patients (91.4%) without preopera-
tive paresis showed no surgery-related change in motor function 
on long-term follow-up (p = 0.4414; Figure 4A).
With regard to the non-nTMS group, there was no significant 
correlation between preoperative and new surgery-related 
paresis. Five patients (9.8%) in the non-nTMS group with 
preoperative paresis deteriorated permanently, compared to 
12 patients (15.2%) without preoperative paresis. Two patients 
(3.9%) with paresis and 3 patients (3.8%) without paresis showed 
a transient surgery-related paresis, while 44 patients (86.3%) with 
and 64 patients (81.0%) without preoperative paresis showed no 
surgery-related change in motor function on long-term follow-
up (p = 0.6730; Figure 4B).
FigUre 4 | Preoperative paresis vs. permanent surgery-related deficit. This bar chart shows the percentage of patients with and without a preoperative 
paresis in the navigated transcranial magnetic stimulation (nTMS) (a) and the non-nTMS group (B). On long-term follow-up, these pareses can be unchanged, 
transient, or permanent in comparison to the preoperative neurological status.
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Tumor location vs. Permanent  
surgery-related Paresis
The location of the metastasis was not associated with a higher 
rate of permanent new paresis in the nTMS (p = 0.2442) or non-
nTMS group (p = 0.6615).
Permanent new surgery-related  
Deficit vs. eOr
We observed a significantly lower rate of residual tumor in the 
nTMS group (Table 2). There were 9 patients (7.7%) in the nTMS 
and 27 patients (21.6%) in the non-nTMS group with residual 
tumor in postoperative scans (OR 0.3025; CI 0.1356–0.6749). 
Concerning expected EOR, there was no difference between 
groups: for 111 patients (95.7%) in the nTMS and 124 patients 
(96.1%) in the non-nTMS group, the surgeon expected GTR (OR 
0.8952; CI 0.2524–3.175). However, there were 4 patients (3.4%) 
in the nTMS and 23 patients (18.4%) in the non-nTMS group with 
unexpected residual tumor on postoperative MRI (OR 0.1570; CI 
0.0525–0.4694; Table 2). Concerning EOR and the relation to any 
new surgery-related permanent paresis, there was no significant 
difference between the nTMS (OR 0.8182; CI 0.04086–16.38) and 
the non-nTMS group (OR 0.4425; CI 0.1468–1.334) between GTR 
and subtotal resection (STR). However, when comparing new 
surgery-related permanent paresis for the nTMS and non-nTMS 
group separately after GTR and STR, we observed a significantly 
lower rate of new surgery-related permanent paresis in the nTMS 
group (OR 0.3042; CI 0.0935–0.9895). This difference was not 
found in the subgroup of patients who underwent STR (OR 
0.1741; CI 0.0089–3.416; Table 2).
intraoperative Use of neuromonitoring
Since the data were partially analyzed retrospectively, we were 
not able to assess in all cases whether IOM was used or not. Thus, 
in terms of IOM, we only differentiate between “yes” and “no/
data missing.” By doing so, we observed a significantly lower rate 
of IOM in the nTMS group. There were 59 patients (49.2%) in 
the nTMS and 83 patients (62.9%) in the non-nTMS group in 
which IOM was used, while there was no IOM or data missing in 
61 patients (50.8%) in the nTMS and 49 patients (37.1%) in the 
non-nTMS group (OR 0.571; CI 0.3453–0.9441).
DiscUssiOn
The broad spectrum of pathologies within neurooncology 
presents a particular challenge when validating a new technique 
such as nTMS. Variations in tumor location, aggressiveness, and 
prognosis mean that a novel presurgical technique must undergo 
extensive testing in a large cohort before it can be considered 
effective. nTMS has demonstrated benefit in the surgical treat-
ment of eloquent supratentorial primary central nervous system 
(CNS) lesions (2–4). It is as yet unclear whether similar benefit 
exists for the management of eloquent supratentorial metastatic 
lesions (2–4).
In the recent past, surgical resection of metastatic lesions in 
the CNS was undertaken routinely without any sort of IOM. 
Subsequently, studies showed the infiltrative character of brain 
metastases and the value of IOM (19–22). However, convincing 
data on the influence of preoperative mapping on clinical out-
come were not available.
surgical Time
The difference in surgical time that we observed in this study 
may be a result of smaller craniotomy size and a reduced rate of 
intraoperative mapping and monitoring via DCS. Having nTMS 
motor mapping data available, we found that intraoperative map-
ping took on more of a confirmatory than an investigative role. 
Similarly, having preoperative nTMS data allowed for limited 
craniotomy size because larger exposures simply for mapping 
purposes were not required (6). Prior comparisons between large 
cohorts of patients undergoing nTMS and non-nTMS (for various 
primary CNS pathologies including eloquent gliomas) were not 
able to show any significant difference in surgical time (2–4). 
We postulate that this difference is due to the infiltrative nature 
of gliomas—in these cases, surgeons depend on IOM to give 
the most complete resection of abnormal tissue within eloquent 
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cortex. Conversely, in resections of metastatic lesions, the border 
between tumor and non-tumor is usually defined, so mapping 
is most useful only while approaching and accessing the tumor. 
Thus, the surgeon may depend more upon a preoperative nTMS 
map so long as it is confirmed intraoperatively with IOM.
intraoperative neuromonitoring
Although this data set is incomplete, the results reflect a clinical 
experience that became commonplace at each of the participating 
institutions over the course of the study. Namely, when preopera-
tive nTMS maps clearly demonstrate the functional anatomy, they 
can then be swiftly confirmed after craniotomy (before tumor 
resection) and extensive motor mapping (or in some cases even 
motor monitoring) becomes superfluous (Figure 1). This experi-
ence is also reflected in the shorter surgical time of the nTMS 
group. However, it must be emphasized that nTMS is not meant to 
replace DCS mapping nor motor monitoring. Instead, our find-
ings show that nTMS can help to identify patients in which DCS 
mapping or motor monitoring might be unnecessary because 
of the distance between lesion and functionally eloquent motor 
regions. Similarly, if the lesion is in close proximity to eloquent 
motor regions, nTMS can make intraoperative DCS more targeted 
and therefore quicker. Both these situations result in shorter sur-
gical times and a higher level of certainty regarding the location of 
functional tissue in the nTMS cohort. It must also be mentioned 
that, in some cases, nTMS identifies a previously unrecognized 
motor region, thus leading to DCS mapping or motor monitoring 
where it might not have been otherwise employed. Thus, nTMS 
should be regarded as a supplementary tool, which complements 
IOM and improves patient safety.
craniotomy
Since extensive intraoperative mapping is usually not required 
when nTMS data are available, the surgeon can limit the craniot-
omy to the tumor instead of additionally exposing the precentral 
gyrus. This effect on craniotomy size with respect to the exposure 
of primary motor cortex is reflected in the smaller AP craniotomy 
extension compared to the lateral craniotomy extension when 
comparing the nTMS to the non-nTMS group (Figure 2).
Tumor residual
The EOR that we observed in this study is in accordance with 
other studies on the effect of mapping on EOR (2–4, 23–25). 
Studies have shown conclusively that IOM results in greater EOR 
(6, 23, 26); how the addition of preoperative mapping further 
improves EOR is not as obvious. Most likely, the concordance of a 
preoperative, nTMS-based map with an intraoperative DCS map 
offers greater confidence in the cortical and subcortical anatomy, 
thereby leading to more extensive resection.
new surgery-related Pareses
Average follow-up was comparable in both groups and suffi-
ciently long to exclude further recovery of motor function. Thus, 
the observed long-term pareses can be judged as permanent 
(Table 2).
By showing that preoperative mapping reduces the risk of 
surgery-related deficits, this study correlates well with other 
available studies by Duffau, De Witt Hamer, and others prov-
ing that additional functional mapping reduces surgery-related 
pareses in patients with motor eloquent lesions (2, 4, 23–25). 
The rates of postoperative neurological improvement in the 
nTMS group were more than twice that of the non-nTMS group 
(Figure  3; Table  2). The overall high improvement rate is well 
in accordance with other data on brain metastases (1, 19). 
However, significant difference in improvement between nTMS 
and non-nTMS patients bears additional discussion (Figure  3; 
Table 2). In general, reducing the mass effect and tumor-induced 
edema of brain metastases causes recovery of the motor system 
in many cases. Previous studies in glioma patients have shown 
that nTMS data, especially when combined with DTI FT, changes 
the surgical approach in a considerable number of cases because 
functional motor tracts were identified in unexpected locations. 
Thus, approach planning in the non-nTMS group can put at risk 
both the motor eloquent cortex and the CST. We hypothesize that 
this additional benefit of nTMS explains the differential rates of 
motor recovery between the two groups (Figure 3; Table 2).
alternative Mapping Techniques
nTMS is not the only non-invasive technique to map cortical 
motor function. Other techniques are MEG and fMRI. fMRI is a 
very broadly available and frequently used modality. Some studies 
showed a good correlation between fMRI and intraoperative DCS 
in identifying the primary motor cortex (6, 16, 27–29). However, 
in contrast to MEG and nTMS, fMRI does not gauge electrophysi-
ological cortical function. Rather, it visualizes increased oxygen 
consumption, which is a proxy for metabolic demand, which 
is a proxy for neurological activation. Thus fMRI is a surrogate 
parameter, and it can be severely influenced by ischemia, tumor 
infiltration, or edema, which can interfere with measurement of 
cortical function (30). For this reason, current consensus is that 
fMRI lacks the sensitivity and specificity to guide surgical resec-
tion in cortical areas adjacent to intracerebral lesions, and fMRI 
alone is not used for surgical planning (31–34).
In contrast, MEG has been shown to correlate well with 
both DCS and nTMS in mapping motor eloquent cortex (35). 
However, due to the high cost of MEG facilities, the availability 
of this modality to the majority of brain tumor patients is limited. 
nTMS, on the other hand, is comparably economical and easy to 
use. Thus, its widespread availability opens new options for non-
invasive mapping. Because it relies on MEPs, it is a true test of 
function rather than a proxy for function. As such, its methodol-
ogy is comparable to DCS, the gold standard in the neurosurgical 
community (36–40).
limitations of Our Data
Since nTMS and the intraoperative use of the functional data 
requires neuronavigation, the precision of intraoperatively 
displayed motor mapping data can be impaired by several con-
founding factors. First of all, these data harbor the accumulated 
registration errors and navigation errors of the nTMS and the 
intraoperative neuronavigation system. Moreover, intraoperative 
neuronavigation usually shows brain shift beginning at some 
point after durotomy (41, 42). However, since brain shift occurs 
some time after durotomy, it does not weaken the practical use 
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Another limitation of our results is that the intraoperative 
use of IOM could not be evaluated completely. For example, 
data regarding the type of IOM, the frequency of stimulation, 
the extent of mapping, etc., were not available for analysis. It 
should be noted, however, that the main focus of this study was 
not to compare techniques of IOM, but rather to delineate the 
impact of adding preoperative nTMS to the current standard 
of care. Despite the observed lower rate of IOM in the nTMS 
group, the influence of nTMS data on IOM has to be evaluated 
in a separate study in order to obtain more reliable data since 
this issue was not the main focus of the study reported in this 
manuscript.
This study is also subjected to the limits of a prospective, non-
randomized observational cohort study. In order to demonstrate 
conclusively the value of nTMS, a randomized controlled trial 
comparing patients with or without nTMS is required. It should 
be noted, however, that neither DCS nor intraoperative neuro-
navigation have level I evidence yet both are considered standard 
of care seen as mandatory by most neurosurgeons. For intraop-
erative mapping by DCS the best existing level of evidence is also 
a matched pair analysis with a historic control group (23). Thus, 
while a randomized controlled trial as discussed earlier would be 
ideal, we encourage clinicians not to wait for such a trial to adopt 
nTMS into routine clinical practice.
Nonetheless, a randomized trial would also help us to look 
further into important questions raised by the data of this study, 
such as “What is the value of nTMS in decision making to offer 
surgery versus radiosurgery or radiation therapy alone to lesions 
in eloquent cortex?” or “How many patients were considered for 
surgical resection and aborted due to results of nTMS?”
Perspective of nTMs in neurosurgery
The use of nTMS as a preoperative mapping tool in neurosurgi-
cal patients has gained attention in the last 5 years. During this 
time, the benefits of having precise preoperative functional 
data— especially for motor function—have gained widespread 
recognition. These maps offer an unprecedented ability to identify 
functional motor pathways and visualize the spatial relationships 
between tumor and adjacent eloquent structures. This ability has 
implications not only for preoperative and intraoperative plan-
ning but also for the discussion of perioperative risk. Thus, the 
value of nTMS data cannot be measured by outcome data alone; it 
also allows for better patient preparation. Furthermore, it fosters 
a frank discussion between patient and surgeon regarding the 
risk–benefit ratio of radical tumor resection vs. preservation of 
function.
Studies have demonstrated that nTMS improves functional 
and oncological outcome for patients with motor eloquent 
primary CNS lesions (2–4). This study demonstrates similar 
benefit within the subgroup of patients with metastases. From 
an oncological perspective, nTMS opens up the potential for 
tracking tumor-induced plasticity and reorganization of the 
motor system. The occurrence of such functional reorganiza-
tion has been described using IOM; gaining this information 
non-invasively, however, would allow a clinician to identify the 
earliest time point after an initial STR when a repeat resection 
might confer maximal benefit with minimal risk (5, 43–47).
cOnclUsiOn
This non-randomized study suggests that preoperative motor 
mapping by nTMS may improve the treatment of patients under-
going surgical resection of metastases in peri-Rolandic regions. 
These findings suggest that further evaluation with a prospective, 
randomized trial may be warranted. Further study would also 
allow for quantification of the economic impacts of shorter surgi-
cal time, a reduced need for intraoperative DCS mapping, and 
improved patient experience during the perioperative period.
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